<unk>  is an anti neoplastic that is FDA approved for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality..   Common adverse reactions include abdominal pain,  nausea, myalgia, asthenia, headache, bladder pain, cystitis, dysuria,  hematuria, incontinence, increased frequency of urination, pain in urethra, burning sensation,  malaise.
Valrubicin
Pirarubicin
Epirubicin
Amrubicin
Aclarubicin
Idarubicin hydrochloride
Epirubicin hydrochloride
Zorubicin